Viewing nowCombinationExrofine Tablet 10/160 mg
Amlodipine Besylate 13.87mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Hubist Pharmaceutical Co., Ltd.

MFDS item code 201607211 · Approved 2016.12.21 · Insurance code 628800850
Treatment of essential hypertension not controlled with monotherapy
This medication is used to effectively lower blood pressure in patients whose blood pressure is not sufficiently controlled by monotherapy with amlodipine or valsartan. It helps patients with essential hypertension manage their blood pressure more stably. Therefore, this drug is useful for improving blood pressure control.
The recommended dose is 1 tablet once daily, taken with water, with or without food. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or valsartan). However, if blood pressure is not controlled with monotherapy using an individual component, switching directly to this medicine may be considered as follows. ㆍ5/80 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy. ㆍ5/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg monotherapy. ㆍ10/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg monotherapy, or with 5/160 mg. Patients taking valsartan and amlodipine concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or greater). However, this medicine should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or patients receiving dialysis. Monitoring of potassium levels and creatinine is recommended in patients with moderate renal impairment. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80mg. This medicine should not be administered to patients with severe hepatic impairment, biliary cirrhosis, or biliary obstruction/cholestasis. Patients aged 65 years or older: Use caution when increasing the dose.
Use of this medicine is not recommended in pediatric patients under 18 years of age because its safety and efficacy have not been established.
This drug can cause severe harm to the fetus if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients who have allergies to this drug's components or similar medications, pregnant or breastfeeding women, patients with severe renal or liver dysfunction, and patients with certain heart diseases should not take this medication. Patients with low sodium or fluid levels in the body should improve their condition before taking this medication, and if symptoms of hypotension appear during use, they should lie down immediately and seek medical treatment if necessary. Patients with high potassium levels or those taking medications that may increase potassium levels should have their potassium levels checked frequently. Patients with problems in renal blood vessels or those who have recently undergone kidney transplants should exercise caution as this medication may affect kidney function. This medication can cause angioedema, which involves symptoms such as swelling of the face, lips, or tongue; if these symptoms occur, the medication should be discontinued immediately. Patients with heart failure or post-myocardial infarction should closely monitor changes in kidney function while taking this medication, and acute myocardial infarction patients should be cautious as this medication may exacerbate angina or myocardial infarction. Co-administration with other RAAS acting drugs during hypertension treatment may increase the risk of hypotension, worsening renal function, and hyperkalemia, so co-administration should be avoided, and if unavoidable, blood pressure and renal function should be tested frequently. Caution should be exercised as dizziness or fatigue may occur during driving or operating machinery. In patients with compromised liver function, the dosage should be limited, and in cases of overdose, hypotension, increased heart rate, and in severe cases, shock may occur, requiring immediate medical treatment. Additionally, this drug is not recommended for children under 18 years of age as safety and efficacy have not been adequately established.
Nasopharyngitis, influenza, hypersensitivity, visual impairment, anxiety, headache, dizziness, drowsiness, positional vertigo, paresthesia, lightheadedness, tinnitus, tachycardia, palpitations, syncope, orthostatic hypotension, hypotension, cough, pharyngeal and laryngeal pain, diarrhea, nausea, abdominal pain, constipation, dry mouth, rash, erythema, hyperhidrosis, rash, pruritus, joint swelling, low back pain, arthritis, muscle spasms, lethargy, polyuria, nocturia, erectile dysfunction, edema, angioedema, facial edema, peripheral edema, fatigue, flushing, weakness, facial flushing, decreased hemoglobin, decreased hematocrit, neutropenia, thrombocytopenia, hypersensitivity including serum sickness, increased serum potassium, vasculitis, elevated liver function tests, vascular edema, bullous dermatitis, myalgia, renal failure, kidney damage, elevated serum creatinine, insomnia, decreased libido, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, viral infection, intestinal vascular edema, diplopia, thrombocytopenia, leukopenia, allergic reaction, hyperglycemia, insomnia, mood changes, tremors, sensory loss, dysgeusia, peripheral neuropathy, hypertonicity, arrhythmia, bradycardia, atrial fibrillation, ventricular tachycardia, myocardial infarction, vasculitis, dyspnea, rhinitis, vomiting, dyspepsia, pancreatitis, gastritis, gingival hyperplasia, hepatitis, jaundice, alopecia, purpura, skin depigmentation, photosensitivity reaction, vascular edema, urticaria, erythema multiforme, Stevens-Johnson syndrome, myalgia, dysuria, enuresis, gynecomastia, pain, malaise, chest pain, weight loss, weight gain, increased liver enzymes, chest discomfort, abdominal discomfort, gastroesophageal reflux disease, neck pain, hypercholesterolemia, hypoglycemia, nervous irritability, sensory loss, Stevens-Johnson syndrome, chest pain, weight gain, arthralgia, skeletal pain, rhabdomyolysis, gingival hyperplasia, gastritis
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container to protect it from exposure to air or moisture. It is important to maintain storage temperature at room temperature between 1°C and 30°C. This will help preserve the effectiveness and safety of the medication for a longer period.
Bright yellow oval film-coated tablet
28 tablets (14 tablets/Alu-Alu X 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 13.87mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Hubist Pharmaceutical Co., Ltd.
CombinationValsartan 160mg · Amlodipine Besylate 6.94mg
Tablet · Prescription medication · Combination
Novartis Korea Co., Ltd.
CombinationValsartan 80mg · Amlodipine Besylate 6.94mg
Tablet · Prescription medication · Combination
Korea Novartis Co., Ltd.
CombinationValsartan 160mg · Amlodipine Besylate 13.87mg
Tablet · Prescription medication · Combination
Novartis Korea Co., Ltd.
Valsartan · Amlodipine Besylate
Prescription medication · Combination
Korea Sandose Co., Ltd.
Valsartan · Amlodipine Besylate
Prescription medication · Combination
Korea Sandos Co., Ltd.
Valsartan · Amlodipine Besylate
Prescription medication · Combination
Korea Sandos Co., Ltd.
CombinationValsartan 160mg · Amlodipine Besylate 13.87mg
Tablet · Prescription medication · Combination
Myungmoon Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.